Core Insights - Defence Therapeutics Inc. has announced the conversion of its 8% convertible debentures into common shares, totaling 2,607,600 shares upon maturity on November 16, 2025 [1][2] Group 1: Financial Details - The principal amount of $1,476,000 was converted into 2,460,000 shares at a conversion price of $0.60 per share [2] - An aggregate amount of $118,080 of accrued interests was converted into 147,600 shares at $0.80 per share, bringing the total conversion value to $1,594,080 [2] Group 2: Company Overview - Defence Therapeutics is a publicly-traded biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology [3] - The ACCUM® technology allows for precision delivery of ADCs to target cells, enhancing efficacy and potency against cancer [3]

Core Insights - Defence Therapeutics Inc. successfully presented new data on its proprietary Accum® platform at the 16th World ADC Conference in San Diego, generating significant interest from the scientific and industry communities [2][3]. Company Developments - The presentation highlighted how Accum® enhances intracellular delivery and payload release, improving the potency and therapeutic index of antibody-drug conjugates (ADCs) [3]. - The company plans to expand testing of Accum® across a wider range of commercial and clinical-stage ADCs to validate its potential in enhancing efficacy and patient outcomes [4]. - Defence Therapeutics aims to demonstrate that Accum® can universally enhance ADC performance, regardless of the payload or antibody used, and is engaging with industry partners to accelerate evaluations [5]. Technology Overview - The Accum® technology is designed for precision delivery of ADCs in their intact form to target cells, which can lead to increased efficacy and potency against cancer [6].

Core Insights - Defence Therapeutics Inc. is participating in CPHI Worldwide 2025, a major global pharmaceutical trade fair in Frankfurt, Germany from October 28-30, 2025 [1][2] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells, thereby increasing efficacy against cancer [6] Event Participation - The company aims to engage with potential partners across the biopharma value chain and connect with the global pharmaceutical community to learn about the latest trends in pharmaceutical manufacturing [2] - Defence Therapeutics is hosting a Meet & Greet event on October 29, 2025, from 4:30-6:30 PM at the Kimpton Hotel in Frankfurt, providing an informal setting for networking and exploring partnership opportunities [3][4] CPHI Overview - CPHI is a leading global pharmaceutical trade show expected to attract over 62,000 visitors and around 2,400 exhibiting companies in 2025, featuring more than 180 international speakers [5]

Core Insights - Defence Therapeutics Inc. has appointed Dr. Amie Phinney to its Board of Directors, effective immediately, to enhance governance and long-term value creation as the company advances its drug-delivery platform [1][2][3] Group 1: Leadership Changes - Dr. Phinney previously served as a Strategy and Business Advisor and will now play a crucial role on the Board, contributing to strategic priorities and governance [2][3] - The CEO of Defence Therapeutics, Sébastien Plouffe, emphasized Dr. Phinney's significant impact on the company's strategic direction and her valuable experience in global pharma and biotech [3] Group 2: Incentives and Compensation - The company has granted Dr. Phinney 100,000 incentive stock options, which are vested immediately and exercisable at a price of $0.75 per share for three years [4] Group 3: Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which allows for precision delivery to target cells, enhancing efficacy against cancer [5]

Group 1 - Defence Therapeutics Inc. has successfully closed a non-brokered private placement of debenture units, raising a total of $2,000,000 [1][5] - Each debenture unit consists of one $1,000 principal amount 8.0% convertible debenture and 1,666 common share purchase warrants [1][2] - The debentures have a maturity date of September 15, 2027, and are convertible into common shares at a price of $0.60 per share [2][3] Group 2 - The company paid a total of $160,000 in cash finder's fees and issued 266,667 finder's warrants, which are also exercisable at $0.75 per share [4] - The net proceeds from the offering will be used to advance the company's science programs and for general working capital [5] - All securities issued are subject to a statutory hold period of four months plus a day from their date of issue [5] Group 3 - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology [7]

Company Overview - Defence Therapeutics Inc. is a clinical-stage biotechnology company focused on drug delivery technologies, particularly in developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells, thereby increasing efficacy against cancer [5]. Leadership Appointment - Dr. Amie Phinney has been appointed as the Strategy & Business Advisor to guide Defence Therapeutics in its next phase of growth, effective immediately [1]. - Dr. Phinney brings over 20 years of experience in life sciences commercialization, having held significant roles in pharmaceutical R&D and biotech innovation at companies like Abbott and AbbVie [2][3]. Strategic Vision - The company is at a pivotal point, with its scientific advancements opening new transformative opportunities. Dr. Phinney's expertise in both scientific and strategic leadership is expected to help the company capture this momentum for sustainable growth [4]. - Dr. Phinney expressed enthusiasm about joining Defence Therapeutics, highlighting the potential of the company's science to transform the field of antibody-delivered therapeutics and her commitment to building a roadmap for innovation [4].

Core Viewpoint - Defence Therapeutics Inc. is conducting a non-brokered private placement of debenture units to raise up to $1,200,000, aimed at enhancing its drug delivery technologies [1][2]. Financing Details - The offering consists of debenture units priced at $1,000 each, with a total gross proceeds target of $1,200,000 [1]. - Each unit includes one $1,000 principal amount of an 8.0% convertible debenture and 1,666 common share purchase warrants [1][2]. - The debentures will bear an interest rate of 8.0% per annum and will mature two years from the issue date [2]. - The principal amount of each debenture is convertible into common shares at a conversion price of $0.60 per share [2]. - Accrued interest can be paid annually in shares at the conversion price or in cash at the company's discretion [2]. Warrant Details - Each warrant allows the holder to acquire one common share at an exercise price of $0.75 for a period of two years from the issue date [3]. Regulatory and Compliance Information - All securities issued will be subject to a statutory hold period of four months and one day following the closing date [4]. - The completion of the offering is contingent upon receiving all necessary regulatory approvals [4]. - The company may pay a finder's fee to eligible arm's length finders in accordance with Canadian Securities Exchange policies [4]. Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells, thereby increasing efficacy against cancer [6].

Core Insights - Defence Therapeutics Inc. has appointed Dr. Elias Theodorou as Chief Operating Officer, effective April 2025, to enhance its management team and accelerate development programs [2][3] - Dr. Theodorou brings over 25 years of experience in cancer research and innovative drug delivery systems, which aligns with Defence's mission to advance its proprietary Accum® technology [3][4] - The company has granted Dr. Theodorou 350,000 incentive stock options, with 100,000 vesting immediately and the remainder vesting in one year, exercisable at $1.07 per share for ten years [3] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing radio-immuno-conjugate and antibody-drug conjugate (ADC) products using its proprietary platform [4] - The core technology, Accum®, enables precision delivery of therapeutic agents to target cells, aiming to improve efficacy against cancer and infectious diseases [5]